Search

everythinglearnresearchcommunity

for

Search:↓

Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.

Early treatment with certain drug combinations improved COVID-19 outcomes and prevented severe disease in males, including those at higher risk.

Men with male pattern baldness had worse COVID-19 symptoms, but early treatment with certain drugs improved outcomes for all.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

The authors maintain that shorter androgen receptor alleles may lead to milder COVID-19 by positively affecting the immune response, not due to changes in testosterone levels or activity.

The AndroCoV Clinical Scoring is a quick, accurate, and free tool for diagnosing COVID-19.

The AndroCoV Clinical Scoring is an accurate, easy, and free way to diagnose COVID-19 without a lab test.

The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.

The AndroCoV Clinical Scoring is a quick, affordable, and accurate method for diagnosing COVID-19.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

The study concludes that the new clinical scoring system is a quick, low-cost, and accurate method for diagnosing COVID-19.

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

Early treatment with azithromycin and other drugs reduced COVID-19 symptoms and complications.

COVID-19 may worsen with androgens; anti-androgen drugs could help.

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

COVID-19 can cause hair loss, and treatments like PRP and stem cells might help.

The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.

People with diabetes or obesity should manage their conditions carefully as they have a higher risk of severe COVID-19.

Anabolic steroid users may face higher risk of severe COVID-19.

Dutasteride shows promise as a potential treatment for Parkinson's disease.

Higher dihydrotestosterone may be linked to more inflammation in COVID-19 patients with low testosterone.

Hormonal status from androgen deprivation therapy may affect COVID-19 severity in men.

Possible link between androgens and COVID-19 severity; more research needed.

Sex hormones' effects on COVID-19 are unclear and more research is needed to understand their potential as treatment.

Antiandrogens don't help with COVID-19 and aren't recommended.